Jonathan Michael Yingling Net Worth

The estimated Net Worth of Jonathan Michael Yingling is at least $10.1 Тысяча dollars as of 7 January 2020. Jonathan Yingling owns over 1,742 units of Idera Pharmaceuticals stock worth over $7,034 and over the last 8 years Jonathan sold IDRA stock worth over $3,101.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jonathan Yingling IDRA stock SEC Form 4 insiders trading

Jonathan has made over 1 trades of the Idera Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Jonathan sold 1,742 units of IDRA stock worth $3,101 on 7 January 2020.

The largest trade Jonathan's ever made was selling 1,742 units of Idera Pharmaceuticals stock on 7 January 2020 worth over $3,101. On average, Jonathan trades about 249 units every 0 days since 2017. As of 7 January 2020 Jonathan still owns at least 16,358 units of Idera Pharmaceuticals stock.

You can see the complete history of Jonathan Yingling stock trades at the bottom of the page.

What's Jonathan Yingling's mailing address?

Jonathan's mailing address filed with the SEC is 505 Eagleview Blvd, Exton, PA 19341, USA.

Insiders trading at Idera Pharmaceuticals

Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... и Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.

What does Idera Pharmaceuticals do?

Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.

Complete history of Jonathan Yingling stock trades at Idera Pharmaceuticals

Idera Pharmaceuticals executives and stock owners

Idera Pharmaceuticals executives and other stock owners filed with the SEC include:

• Vincent Milano,
  President, Chief Executive Officer, Director
• Robert Fletcher,
  Senior Vice President - Business Development and Strategic Planning
• Bryant Lim,
  Senior Vice President, General Counsel, Corporate Secretary
• John Kirby,
  Chief Financial Officer, Senior Vice President
• Bryant David Lim,
  Sr. VP, Gen. Counsel & Corp. Sec.
• John J. Kirby,
  Sr. VP & CFO
• Vincent J. Milano,
  Pres, CEO & Director
• james Geraghty,
  Independent Chairman of the Board
• Carol Schafer,
  Independent Director
• Maxine Gowen,
  Independent Director
• Mark Goldberg,
  Independent Director
• Michael Dougherty,
  Independent Director
• Cristina Csimma,
  Independent Director
• Elizabeth Tarka,
  Senior Vice President, Chief Medical Officer
• Louis J. Arcudi III, M.B.A., MBA,
  Adviser
• Dr. Sudhir Agrawal D.Phil., DPHIL, F.R.S.C.,
  Scientific Advisor
• Dr. Sudhir Agrawal,
  Scientific Advisor
• Dr. Joanna C. Horobin Ch.B, M.B.,
  Advisor
• Dr. Shah Rahimian M.D., Ph.D.,
  Medical Director & Global Clinical Lead for Oncology
• Elizabeth Eberhardt,
  Sr. VP of Product Leadership
• Jill Conwell,
  Sr. VP of Investor Relations & Corp. Communications
• Daniel B. Soland,
  Sr. VP & COO
• Bros. Advisors Lp667, L.P.B...,
  
• William S Reardon,
  Director
• Invest Corp Pillar Pharmace...,
  
• Iii Louis J Arcudi,
  Chief Financial Officer
• Julianbaker Bros. Advisors ...,
  
• Invest Corp Pillar Pharmace...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Invest Corp Pillar Pharmace...,
  
• Mark J Casey,
  Senior VP and General Counsel
• Julian Baker Bros. Advisors...,
  
• Youssef El Zein,
  Director
• Bros. Advisors Lp Baker Bro...,
  
• Alice Bexon,
  V.P. Clinical Development
• Alison Taunton Rigby,
  Director
• Sudhir Agrawal,
  CEO & CSO
• Invest Corp Pillar Pharmace...,
  
• Bros. Advisors Lp14159, L.P...,
  
• Invest Corp Pillar Pharmace...,
  
• Invest Corp Pillar Pharmace...,
  
• Jonathan Michael Yingling,
  Chief Scientific Officer
• Invest Corp Pillar Pharmace...,
  
• Invest Corp Pillar Pharmace...,
  
• Howard H Pien,
  Director
• Invest Corp Pillar,
  10% owner
• Paul C Zamecnik,
  
• Joanna Horobin,
  SVP and Chief Medical Officer
• Eve Elizabeth Slater,
  Director
• Malcolm Mac Coss,
  Director
• Timothy M Sullivan,
  VP Development Programs
• Umari Abdul Wahab,
  Director
• Louis Md Brenner,
  Chief Medical Officer
• Robert D. Arbeit,
  VP Clinical Development
• Robert W Karr,
  Director
• Pharmaceuticals I Lpzein Yo...,
  
• John Peter Iii Wolf,
  General Counsel
• Invest Corp Pillar Pharmace...,
  
• C Keith Hartley,
  Director
• Investment Group Lp Senator,
  10% owner
• Invest Corp Zein Youssef El...,
  
• Hans Mueller,
  Director
• James B Wyngaarden,
  Director
• Invest Corp Pillar Pharmace...,
  
• Invest Corp Pillar Partners...,
  
• Invest Corp Pillar Partners...,
  
• Daniel B Soland,
  CHIEF OPERATING OFFICER
• John Clayton Taylor,
  Chief Executive Officer
• Ronald J Wooten,
  Director
• Carl N Kraus,
  Chief Medical Officer
• Daniel Salain,
  Chief Operating Officer
• Co Investment Fund Xv, L.P....,